Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 102

1.

Oligonucleotide Treatment for Huntington's Disease.

Fischbeck KH, Wexler NS.

N Engl J Med. 2019 Jun 13;380(24):2373-2374. doi: 10.1056/NEJMe1904861. Epub 2019 May 6. No abstract available.

PMID:
31059640
2.

Xyloketal-derived small molecules show protective effect by decreasing mutant Huntingtin protein aggregates in Caenorhabditis elegans model of Huntington's disease.

Zeng Y, Guo W, Xu G, Wang Q, Feng L, Long S, Liang F, Huang Y, Lu X, Li S, Zhou J, Burgunder JM, Pang J, Pei Z.

Drug Des Devel Ther. 2016 Apr 13;10:1443-51. doi: 10.2147/DDDT.S94666. eCollection 2016.

3.

Treating Huntington's with oligonucleotides.

Stower H.

Nat Med. 2019 Jun;25(6):877. doi: 10.1038/s41591-019-0491-6. No abstract available.

PMID:
31171870
4.

Translating Antisense Technology into a Treatment for Huntington's Disease.

Lane RM, Smith A, Baumann T, Gleichmann M, Norris D, Bennett CF, Kordasiewicz H.

Methods Mol Biol. 2018;1780:497-523. doi: 10.1007/978-1-4939-7825-0_23. Review.

PMID:
29856033
5.

Phosphorylation of huntingtin at residue T3 is decreased in Huntington's disease and modulates mutant huntingtin protein conformation.

Cariulo C, Azzollini L, Verani M, Martufi P, Boggio R, Chiki A, Deguire SM, Cherubini M, Gines S, Marsh JL, Conforti P, Cattaneo E, Santimone I, Squitieri F, Lashuel HA, Petricca L, Caricasole A.

Proc Natl Acad Sci U S A. 2017 Dec 12;114(50):E10809-E10818. doi: 10.1073/pnas.1705372114. Epub 2017 Nov 21.

6.

Huntingtin protein: A new option for fixing the Huntington's disease countdown clock.

Caterino M, Squillaro T, Montesarchio D, Giordano A, Giancola C, Melone MAB.

Neuropharmacology. 2018 Jun;135:126-138. doi: 10.1016/j.neuropharm.2018.03.009. Epub 2018 Mar 8. Review.

PMID:
29526547
7.

Embryonic Mutant Huntingtin Aggregate Formation in Mouse Models of Huntington's Disease.

Osmand AP, Bichell TJ, Bowman AB, Bates GP.

J Huntingtons Dis. 2016 Dec 15;5(4):343-346.

8.

How the gene behind Huntington's disease could be neutralized.

Drew L.

Nature. 2018 May;557(7707):S39-S41. doi: 10.1038/d41586-018-05176-z. No abstract available.

PMID:
29844556
9.

Huntington's disease: 4 big questions.

Nowogrodzki A.

Nature. 2018 May;557(7707):S48. doi: 10.1038/d41586-018-05180-3. No abstract available.

PMID:
29844555
10.

Short G-rich oligonucleotides as a potential therapeutic for Huntington's Disease.

Skogen M, Roth J, Yerkes S, Parekh-Olmedo H, Kmiec E.

BMC Neurosci. 2006 Oct 2;7:65.

11.

Huntington's Disease: The Most Curable Incurable Brain Disorder?

Wild EJ.

EBioMedicine. 2016 Jun;8:3-4. doi: 10.1016/j.ebiom.2016.05.023. Epub 2016 May 19. No abstract available.

12.

Piecing together the puzzle of Huntington's disease.

DeWeerdt S.

Nature. 2018 May;557(7707):S36-S37. doi: 10.1038/d41586-018-05174-1. No abstract available.

PMID:
29844552
13.

Visualization of prion-like transfer in Huntington's disease models.

Jansen AH, Batenburg KL, Pecho-Vrieseling E, Reits EA.

Biochim Biophys Acta Mol Basis Dis. 2017 Mar;1863(3):793-800. doi: 10.1016/j.bbadis.2016.12.015. Epub 2016 Dec 29. Review.

14.

Therapies targeting DNA and RNA in Huntington's disease.

Wild EJ, Tabrizi SJ.

Lancet Neurol. 2017 Oct;16(10):837-847. doi: 10.1016/S1474-4422(17)30280-6. Epub 2017 Sep 12. Review. Erratum in: Lancet Neurol. 2017 Dec;16(12 ):954.

15.

Huntingtin interacting protein HYPK is a negative regulator of heat shock response and is downregulated in models of Huntington's Disease.

Das S, Bhattacharyya NP.

Exp Cell Res. 2016 May 1;343(2):107-117. doi: 10.1016/j.yexcr.2016.03.021. Epub 2016 Mar 23.

PMID:
27017930
16.

"Huntingtin holiday": progress toward an antisense therapy for Huntington's disease.

Lu XH, Yang XW.

Neuron. 2012 Jun 21;74(6):964-6. doi: 10.1016/j.neuron.2012.06.001.

17.

Does tissue transglutaminase play a role in Huntington's disease?

Lesort M, Chun W, Tucholski J, Johnson GV.

Neurochem Int. 2002 Jan;40(1):37-52. Review.

PMID:
11738471
18.

Mouse Models of Huntington's Disease.

Farshim PP, Bates GP.

Methods Mol Biol. 2018;1780:97-120. doi: 10.1007/978-1-4939-7825-0_6. Review.

PMID:
29856016
19.

Transcriptional profiles for distinct aggregation states of mutant Huntingtin exon 1 protein unmask new Huntington's disease pathways.

Moily NS, Ormsby AR, Stojilovic A, Ramdzan YM, Diesch J, Hannan RD, Zajac MS, Hannan AJ, Oshlack A, Hatters DM.

Mol Cell Neurosci. 2017 Sep;83:103-112. doi: 10.1016/j.mcn.2017.07.004. Epub 2017 Jul 23.

PMID:
28743452
20.

Luminescent platforms for monitoring changes in the solubility of amylin and huntingtin in living cells.

Zhao J, Vu Q, Stains CI.

Mol Biosyst. 2016 Oct 20;12(10):2984-7. doi: 10.1039/c6mb00454g. Epub 2016 Aug 2.

PMID:
27483434

Supplemental Content

Support Center